Matches in SemOpenAlex for { <https://semopenalex.org/work/W3014348002> ?p ?o ?g. }
- W3014348002 endingPage "192" @default.
- W3014348002 startingPage "184" @default.
- W3014348002 abstract "External beam radiotherapy (EBRT) with neoadjuvant/adjuvant androgen deprivation therapy (ADT) is an established treatment option to prolong survival for patients with intermediate- and high-risk prostate cancer (PCa). Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, was evaluated in this clinical setting in comparison with degarelix, an injectable GnRH antagonist.To evaluate the safety and efficacy of relugolix to achieve and maintain castration.A phase 2 open-label study was conducted in 103 intermediate-risk PCa patients undergoing primary EBRT and neoadjuvant/adjuvant ADT between June 2014 and December 2015.Patients randomly assigned (3:2) to 24-wk treatment with either daily oral relugolix or 4-wk subcutaneous depot degarelix (reference control).The primary endpoint was the rate of effective castration (testosterone <1.73nmol/l) in relugolix patients between 4 and 24 wk of treatment. Secondary endpoints included rate of profound castration (testosterone <0.7nmol/l), prostate-specific antigen (PSA) levels, prostate volume, quality of life (QoL) assessed using the Aging Males' Symptoms scale, and the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life (30-item EORTC core questionnaire [EORTC QLQ-C30] and 25-item EORTC prostate cancer module [EORTC QLQ-PR25]) questionnaires, and safety. No formal statistical comparisons with degarelix were planned.Castration rates during treatment were 95% and 82% with relugolix and 89% and 68% with degarelix for 1.73 and 0.7nmol/l thresholds, respectively. Median time to castration in the relugolix arm was 4 d. During treatment, PSA levels and prostate volumes were reduced in both groups. Three months after discontinuing treatment, 52% of men on relugolix and 16% on degarelix experienced testosterone recovery (statistical significance of differences not tested). Mean and median QoL scores improved following treatment discontinuation. The most common adverse event was hot flush (relugolix 57%; degarelix 61%). Lack of blinding was a potential limitation.Relugolix achieved testosterone suppression to castrate levels within days and maintained it over 24 wk with a safety profile consistent with its mechanism of action.Oral once-daily relugolix may be a novel oral alternative to injectable androgen deprivation therapies." @default.
- W3014348002 created "2020-04-10" @default.
- W3014348002 creator A5011344837 @default.
- W3014348002 creator A5013551992 @default.
- W3014348002 creator A5016944058 @default.
- W3014348002 creator A5020614716 @default.
- W3014348002 creator A5024425081 @default.
- W3014348002 creator A5024685539 @default.
- W3014348002 creator A5025921361 @default.
- W3014348002 creator A5030609617 @default.
- W3014348002 creator A5034389447 @default.
- W3014348002 creator A5041293213 @default.
- W3014348002 creator A5053749991 @default.
- W3014348002 creator A5066752218 @default.
- W3014348002 creator A5067885700 @default.
- W3014348002 creator A5080513675 @default.
- W3014348002 creator A5088518998 @default.
- W3014348002 date "2020-08-01" @default.
- W3014348002 modified "2023-10-14" @default.
- W3014348002 title "The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial" @default.
- W3014348002 cites W1878336561 @default.
- W3014348002 cites W1890874870 @default.
- W3014348002 cites W1930757702 @default.
- W3014348002 cites W1978460595 @default.
- W3014348002 cites W1982946927 @default.
- W3014348002 cites W1984192990 @default.
- W3014348002 cites W1985587689 @default.
- W3014348002 cites W1986114421 @default.
- W3014348002 cites W1994894880 @default.
- W3014348002 cites W1999523955 @default.
- W3014348002 cites W2008203144 @default.
- W3014348002 cites W2016927496 @default.
- W3014348002 cites W2049161486 @default.
- W3014348002 cites W2053371242 @default.
- W3014348002 cites W2069830079 @default.
- W3014348002 cites W2080678621 @default.
- W3014348002 cites W2085147357 @default.
- W3014348002 cites W2090612463 @default.
- W3014348002 cites W2100074173 @default.
- W3014348002 cites W2102333999 @default.
- W3014348002 cites W2106285196 @default.
- W3014348002 cites W2132564643 @default.
- W3014348002 cites W2148386014 @default.
- W3014348002 cites W2156659229 @default.
- W3014348002 cites W2511949746 @default.
- W3014348002 cites W2616333165 @default.
- W3014348002 cites W2772104639 @default.
- W3014348002 cites W2783439285 @default.
- W3014348002 cites W2889865404 @default.
- W3014348002 cites W2945522282 @default.
- W3014348002 doi "https://doi.org/10.1016/j.eururo.2020.03.001" @default.
- W3014348002 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32273183" @default.
- W3014348002 hasPublicationYear "2020" @default.
- W3014348002 type Work @default.
- W3014348002 sameAs 3014348002 @default.
- W3014348002 citedByCount "39" @default.
- W3014348002 countsByYear W30143480022020 @default.
- W3014348002 countsByYear W30143480022021 @default.
- W3014348002 countsByYear W30143480022022 @default.
- W3014348002 countsByYear W30143480022023 @default.
- W3014348002 crossrefType "journal-article" @default.
- W3014348002 hasAuthorship W3014348002A5011344837 @default.
- W3014348002 hasAuthorship W3014348002A5013551992 @default.
- W3014348002 hasAuthorship W3014348002A5016944058 @default.
- W3014348002 hasAuthorship W3014348002A5020614716 @default.
- W3014348002 hasAuthorship W3014348002A5024425081 @default.
- W3014348002 hasAuthorship W3014348002A5024685539 @default.
- W3014348002 hasAuthorship W3014348002A5025921361 @default.
- W3014348002 hasAuthorship W3014348002A5030609617 @default.
- W3014348002 hasAuthorship W3014348002A5034389447 @default.
- W3014348002 hasAuthorship W3014348002A5041293213 @default.
- W3014348002 hasAuthorship W3014348002A5053749991 @default.
- W3014348002 hasAuthorship W3014348002A5066752218 @default.
- W3014348002 hasAuthorship W3014348002A5067885700 @default.
- W3014348002 hasAuthorship W3014348002A5080513675 @default.
- W3014348002 hasAuthorship W3014348002A5088518998 @default.
- W3014348002 hasBestOaLocation W30143480021 @default.
- W3014348002 hasConcept C121608353 @default.
- W3014348002 hasConcept C126322002 @default.
- W3014348002 hasConcept C126894567 @default.
- W3014348002 hasConcept C143998085 @default.
- W3014348002 hasConcept C168563851 @default.
- W3014348002 hasConcept C203092338 @default.
- W3014348002 hasConcept C2775908122 @default.
- W3014348002 hasConcept C2777899217 @default.
- W3014348002 hasConcept C2778043895 @default.
- W3014348002 hasConcept C2779256933 @default.
- W3014348002 hasConcept C2779279991 @default.
- W3014348002 hasConcept C2780192828 @default.
- W3014348002 hasConcept C29456083 @default.
- W3014348002 hasConcept C509974204 @default.
- W3014348002 hasConcept C71315377 @default.
- W3014348002 hasConcept C71924100 @default.
- W3014348002 hasConceptScore W3014348002C121608353 @default.
- W3014348002 hasConceptScore W3014348002C126322002 @default.
- W3014348002 hasConceptScore W3014348002C126894567 @default.
- W3014348002 hasConceptScore W3014348002C143998085 @default.
- W3014348002 hasConceptScore W3014348002C168563851 @default.